Enzymatica Q1 2023: A step in the right direction - Redeye

Redeye provides an update in relation to Enzymatica’s Q1 2023 report. Even if the report was a bit under our expectations, we are positive that the negative effects of the pandemic seem to disappear gradually. The sales during the quarter were SEK13.0m (SEK4.2m), a bit lower than our sales estimate of SEK16.2m, and EBIT came in at SEK-14.4m (SEK-18.1m) compared to our EBIT estimate of SEK-9.7m. We have only made minor changes in our sales and OPEX estimates for 2023. The changes do not render a difference in our valuation; therefore, we reiterate our base case of SEK6.5.

Länk till analysen i sin helhet: https://www.redeye.se/research/898527/enzymatica-q1-2023-a-step-in-the-right-direction?utm_source=finwire&utm_medium=RSS